Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2008
Business Overview: Curis is a drug discovery and development company focused on creating new medicines, primarily for cancer, using innovative signaling pathway drug technologies. The company operates in a single segment and relies on strategic collaborations (notably with Genentech) and internal research programs. As of June 30, 2008, the company had an accumulated deficit of approximately $701.2 million.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2008 | Six Months Ended June 30, 2007 |
|---|---|---|
| Total Revenues | $5,175,393 | $3,591,510 |
| Net Loss | $(5,395,223) | $(7,538,317) |
| Net Loss Per Share (Basic & Diluted) | $(0.09) | $(0.15) |
| Cash and Cash Equivalents (End of Period) | $9,298,426 | $15,167,137 |
| Marketable Securities | $24,615,973 | $24,062,577 |
| Total Current Assets | $34,313,987 | $42,039,096 |
| Total Liabilities | $2,813,284 | $6,972,122 |
| Debt (Current Portion) | $0 | $403,832 |
| Net Cash Used in Operating Activities | $(7,182,282) | $(5,918,131) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 44% to $5.18 million for the six months ended June 30, 2008, compared to $3.59 million in the prior year. This increase was driven primarily by a $3.0 million milestone payment from Genentech for the initiation of a Phase II clinical trial and $1.75 million in license fees recognized from the sale of BMP assets to Stryker Corporation.
- Decline in Contract Revenue: Research and development contract revenues decreased 84% to $323,000, as funding from collaborations with Wyeth and Procter & Gamble concluded.
- Improved Net Loss: Net loss narrowed by approximately 28% to $5.40 million, despite increased R&D spending on internal programs, due to higher revenue recognition and reduced stock-based compensation expenses.
- Debt Repayment: The company fully repaid its short-term debt obligations ($404,000) to Boston Private Bank & Trust Company in April 2008, resulting in zero current debt as of June 30, 2008.
- Cash Burn: Net cash used in operating activities increased to $7.18 million from $5.92 million in the prior year, primarily due to the net loss and decreases in deferred revenue and accounts payable.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management anticipates that existing capital resources (cash, cash equivalents, and marketable securities totaling approximately $33.9 million) will enable the company to maintain operations into the fourth quarter of 2009.
- Future Funding Needs: The company expects to incur substantial operating losses for the foreseeable future. Future funding will depend on new collaborations, equity/debt financings, or contingent payments from existing partners. Additional financing may result in stockholder dilution.
- Development Pipeline:
- Genentech Collaboration: GDC-0449 (Hedgehog antagonist) is in Phase II trials for metastatic colorectal cancer. Genentech plans additional Phase II trials in basal cell carcinoma and ovarian cancer in late 2008.
- Internal Programs: CUDC-101 (HDAC, EGFR, Her2 inhibitor) filed an IND application in May 2008, with Phase I enrollment expected in Q3 2008. CUDC-305 (Hsp90 inhibitor) was selected as a development candidate in July 2008, with an IND filing anticipated in mid-2009.
- Risk Factors:
- Dependence on Genentech for the development of the most advanced product candidate.
- Uncertainty regarding the success of clinical trials and regulatory approvals.
- Need for substantial additional capital to fund operations beyond late 2009.
- Stock price volatility and potential delisting from NASDAQ if the bid price remains below $1.00 for 30 consecutive days.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $33.9 million in liquid assets to fund operations through Q4 2009, considering the high cash burn rate of ~$7.2 million per six months.
- Revenue Sustainability: Assess the likelihood of future milestone payments from Genentech, as current R&D contract revenue has ceased.
- Clinical Trial Progress: Monitor the enrollment and safety data for the CUDC-101 Phase I trial and the Phase II results for GDC-0449.
- Stock Price Compliance: Check current trading prices against the NASDAQ Global Market minimum bid price requirement of $1.00 to evaluate delisting risk.
- Debt Status: Confirm the absence of current debt obligations and the terms of any future financing arrangements.